Zydus Lifesciences submits press release
Zydus Lifesciences has submitted a press release stating that Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg.
The above information is a part of company’s filings submitted to BSE.
